{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:20:29Z","timestamp":1780539629593,"version":"3.54.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/mca.0000000000000409","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T16:40:18Z","timestamp":1467996018000},"page":"604-615","source":"Crossref","is-referenced-by-count":6,"title":["Vorapaxar"],"prefix":"10.1097","volume":"27","author":[{"given":"Leo","family":"Ungar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210204","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"R2-13-20210204","first-page":"e535","article-title":"Correction.","volume":"131","year":"2015","journal-title":"Circulation"},{"key":"R3-13-20210204","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"R4-13-20210204","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"R5-13-20210204","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-13-20210204","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-13-20210204","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association","volume":"58","author":"Smith","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1161\/CIR.0b013e318212bb8b","article-title":"2011 ACCF\/AHA Focused Update Incorporated Into the ACC\/AHA 2007 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","author":"Anderson","year":"2011","journal-title":"Circulation"},{"key":"R10-13-20210204","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"R11-13-20210204","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-13-20210204","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-13-20210204","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jacc.2010.09.065","article-title":"Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery","volume":"57","author":"Storey","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R14-13-20210204","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.10.006","article-title":"Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent","volume":"29","author":"French","year":"2015","journal-title":"Blood Rev"},{"key":"R15-13-20210204","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/13543776.16.4.493","article-title":"Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents","volume":"16","author":"Chackalamannil","year":"2006","journal-title":"Expert Opin Ther Pat"},{"key":"R16-13-20210204","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.bmcl.2005.12.042","article-title":"Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists","volume":"16","author":"Clasby","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"R17-13-20210204","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"R18-13-20210204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11239-012-0750-6","article-title":"Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program","volume":"34","author":"O\u2019Donoghue","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R19-13-20210204","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"},{"key":"R20-13-20210204","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial","volume":"123","author":"O\u2019Donoghue","year":"2011","journal-title":"Circulation"},{"key":"R21-13-20210204","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood-2015-01-623835","article-title":"Partitioning protease signaling","volume":"125","author":"Nieman","year":"2015","journal-title":"Blood"},{"key":"R22-13-20210204","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-13-20210204","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1161\/CIRCULATIONAHA.114.011471","article-title":"Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar","volume":"130","author":"Baker","year":"2014","journal-title":"Circulation"},{"key":"R24-13-20210204","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"R25-13-20210204","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"R26-13-20210204","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.09.005","article-title":"Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke","volume":"21","author":"Shinohara","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R27-13-20210204","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R28-13-20210204","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2048872614527838","article-title":"Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial","volume":"3","author":"Held","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R29-13-20210204","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.amjcard.2014.05.054","article-title":"Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)","volume":"114","author":"Valgimigli","year":"2014","journal-title":"Am J Cardiol"},{"key":"R30-13-20210204","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jacc.2013.10.048","article-title":"Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)","volume":"63","author":"Whellan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R31-13-20210204","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am Heart J"},{"key":"R32-13-20210204","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/eht104","article-title":"Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA\u00b7CER) trial","volume":"34","author":"Leonardi","year":"2013","journal-title":"Eur Heart J"},{"key":"R34-13-20210204","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.amjcard.2013.11.052","article-title":"Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)","volume":"113","author":"Mahaffey","year":"2014","journal-title":"Am J Cardiol"},{"key":"R35-13-20210204","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjcard.2015.02.043","article-title":"Glycoprotein IIb\/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non-ST-segment elevation acute coronary syndromes (from the TRACER Trial)","volume":"115","author":"Cornel","year":"2015","journal-title":"Am J Cardiol"},{"key":"R36-13-20210204","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"R37-13-20210204","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"R38-13-20210204","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"R39-13-20210204","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"R40-13-20210204","doi-asserted-by":"crossref","first-page":"e001505","DOI":"10.1161\/JAHA.114.001505","article-title":"Efficacy and safety of vorapaxar as approved for clinical use in the United States","volume":"4","author":"Magnani","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R41-13-20210204","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.jacc.2014.07.997","article-title":"New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 \u00b0P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R42-13-20210204","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2014.09.037","article-title":"Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2\u00b0 P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R43-13-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamainternmed.2014.5802","article-title":"Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?","volume":"175","author":"Krantz","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R45-13-20210204","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R46-13-20210204","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11886-015-0611-y","article-title":"Limb ischemia: cardiovascular diagnosis and management from head to toe","volume":"17","author":"Vemulapalli","year":"2015","journal-title":"Curr Cardiol Rep"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:40:56Z","timestamp":1620960056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201611000-00013"}},"subtitle":["emerging evidence and clinical questions in a new era of PAR-1 inhibition"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000409","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}